Skip to main content
Top
Published in: Familial Cancer 3/2022

14-09-2021 | Colorectal Cancer | Short Communication

A de novo pathogenic variant in the MSH6 gene in a 52 years-old woman

Authors: Elise Pierre-Noël, Fabrice Airaud, Estelle Cauchin, Céline Garrec, Ingrid Ricordeau, Clémence Michon, Olivier Kerdraon, Stéphane Bezieau, Caroline Abadie

Published in: Familial Cancer | Issue 3/2022

Login to get access

Abstract

Lynch syndrome (LS) is a condition which predisposes individuals primarily to early-onset colorectal and endometrial cancer. LS is characterized by a germline pathogenic variant in one of the MMR (MisMatch Repair) gene, inducing a phenotype of microsatellite instability in the tumor, which may be associated with a loss of expression of MMR proteins detected by standard immunohistochemistry on tumor tissue. Most of the time, LS is inherited from a parent in whom the condition may not be known due to incomplete penetrance, but de novo pathogenic variant is a rare occurrence. Here, we describe the case of a 52-year-old woman with no family history of LS, referred to the genetics department for colorectal cancer at the age of 50. Genetic analysis revealed a de novo germline pathogenic variant in the MSH6 gene. To date, this case is only the second report of a de novo pathogenic variant in the MSH6 gene in Lynch syndrome. De novo mutations have been extensively studied over the past years, but little is known about their origin and mechanism of occurrence in MMR genes. However, knowledge of mutation status allows better cancer risk management for the patient and an appropriate genetic testing and counseling for her family.
Literature
1.
15.
26.
go back to reference Carlson KM, Bracamontes J, Jackson CE et al (1994) Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55:1076–1082PubMedPubMedCentral Carlson KM, Bracamontes J, Jackson CE et al (1994) Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55:1076–1082PubMedPubMedCentral
Metadata
Title
A de novo pathogenic variant in the MSH6 gene in a 52 years-old woman
Authors
Elise Pierre-Noël
Fabrice Airaud
Estelle Cauchin
Céline Garrec
Ingrid Ricordeau
Clémence Michon
Olivier Kerdraon
Stéphane Bezieau
Caroline Abadie
Publication date
14-09-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2022
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-021-00274-w

Other articles of this Issue 3/2022

Familial Cancer 3/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine